320 related articles for article (PubMed ID: 31493469)
21. miRNA and cancer; computational and experimental approaches.
Tutar Y
Curr Pharm Biotechnol; 2014; 15(5):429. PubMed ID: 25189575
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA expression and gene regulation drive breast cancer progression and metastasis in PyMT mice.
Nogales-Cadenas R; Cai Y; Lin JR; Zhang Q; Zhang W; Montagna C; Zhang ZD
Breast Cancer Res; 2016 Jul; 18(1):75. PubMed ID: 27449149
[TBL] [Abstract][Full Text] [Related]
23. Dissecting miRNA facilitated physiology and function in human breast cancer for therapeutic intervention.
Sengupta D; Deb M; Kar S; Pradhan N; Parbin S; Kirtana R; Singh SP; Suma SG; Niharika ; Roy A; Manna S; Saha P; Chakraborty P; Dash S; Kausar C; Patra SK
Semin Cancer Biol; 2021 Jul; 72():46-64. PubMed ID: 32497683
[TBL] [Abstract][Full Text] [Related]
24. Integrated microRNA and mRNA signatures in peripheral blood lymphocytes of familial epithelial ovarian cancer.
Dou YD; Huang T; Wang Q; Shu X; Zhao SG; Li L; Liu T; Lu G; Chan WY; Liu HB
Biochem Biophys Res Commun; 2018 Jan; 496(1):191-198. PubMed ID: 29307835
[TBL] [Abstract][Full Text] [Related]
25. Capn4 expression is modulated by microRNA-520b and exerts an oncogenic role in prostate cancer cells by promoting Wnt/β-catenin signaling.
Ren W; Wang D; Li C; Shu T; Zhang W; Fu X
Biomed Pharmacother; 2018 Dec; 108():467-475. PubMed ID: 30241050
[TBL] [Abstract][Full Text] [Related]
26. Clinical Relevance of microRNA Expressions in Breast Cancer Validated Using the Cancer Genome Atlas (TCGA).
Kim SY; Kawaguchi T; Yan L; Young J; Qi Q; Takabe K
Ann Surg Oncol; 2017 Oct; 24(10):2943-2949. PubMed ID: 28766230
[TBL] [Abstract][Full Text] [Related]
27. Identification of common oncogenic and early developmental pathways in the ovarian carcinomas controlling by distinct prognostically significant microRNA subsets.
Kuznetsov VA; Tang Z; Ivshina AV
BMC Genomics; 2017 Oct; 18(Suppl 6):692. PubMed ID: 28984201
[TBL] [Abstract][Full Text] [Related]
28. Role of microRNAs in cancers of the female reproductive tract: insights from recent clinical and experimental discovery studies.
Logan M; Hawkins SM
Clin Sci (Lond); 2015 Feb; 128(3):153-80. PubMed ID: 25294164
[TBL] [Abstract][Full Text] [Related]
29. Re-evaluation of the roles of DROSHA, Export in 5, and DICER in microRNA biogenesis.
Kim YK; Kim B; Kim VN
Proc Natl Acad Sci U S A; 2016 Mar; 113(13):E1881-9. PubMed ID: 26976605
[TBL] [Abstract][Full Text] [Related]
30. Construction of integrated microRNA and mRNA immune cell signatures to predict survival of patients with breast and ovarian cancer.
Ray M; Ruffalo MM; Bar-Joseph Z
Genes Chromosomes Cancer; 2019 Jan; 58(1):34-42. PubMed ID: 30285311
[TBL] [Abstract][Full Text] [Related]
31. Identifying significant microRNA-mRNA pairs associated with breast cancer subtypes.
Bhattacharyya M; Nath J; Bandyopadhyay S
Mol Biol Rep; 2016 Jul; 43(7):591-9. PubMed ID: 27245063
[TBL] [Abstract][Full Text] [Related]
32. miRNA and long non-coding RNA: molecular function and clinical value in breast and ovarian cancers.
Panoutsopoulou K; Avgeris M; Scorilas A
Expert Rev Mol Diagn; 2018 Nov; 18(11):963-979. PubMed ID: 30338716
[TBL] [Abstract][Full Text] [Related]
33. The diagnostic, prognostic and therapeutic potential of circulating microRNAs in ovarian cancer.
Aboutalebi H; Bahrami A; Soleimani A; Saeedi N; Rahmani F; Khazaei M; Fiuji H; Shafiee M; Ferns GA; Avan A; Hassanian SM
Int J Biochem Cell Biol; 2020 Jul; 124():105765. PubMed ID: 32428568
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-guided gene expression in prostate cancer: Literature and database overview.
Bryzgunova OE; Konoshenko MY; Laktionov PP
J Gene Med; 2018 May; 20(5):e3016. PubMed ID: 29578262
[TBL] [Abstract][Full Text] [Related]
35. Circulating and Tissue microRNAs as Biomarkers for Ovarian Cancer Prognosis.
Parizadeh SM; Jafarzadeh-Esfehani R; Ghandehari M; Hasanzadeh M; Parizadeh SMR; Hassanian SM; Rezaei-Kalat A; Aghabozorgi AS; Rahimi-Kakhki R; Zargaran B; Ferns GA; Avan A
Curr Drug Targets; 2019; 20(14):1447-1460. PubMed ID: 31284859
[TBL] [Abstract][Full Text] [Related]
36. Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management.
van Schooneveld E; Wildiers H; Vergote I; Vermeulen PB; Dirix LY; Van Laere SJ
Breast Cancer Res; 2015 Feb; 17():21. PubMed ID: 25849621
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-27a-5p regulation by promoter methylation and MYC signaling in prostate carcinogenesis.
Barros-Silva D; Costa-Pinheiro P; Duarte H; Sousa EJ; Evangelista AF; Graça I; Carneiro I; Martins AT; Oliveira J; Carvalho AL; Marques MM; Henrique R; Jerónimo C
Cell Death Dis; 2018 Feb; 9(2):167. PubMed ID: 29415999
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA mediated therapeutic effects of natural agents in prostate cancer.
Anjaly K; Tiku AB
Mol Biol Rep; 2021 Jul; 48(7):5759-5773. PubMed ID: 34304390
[TBL] [Abstract][Full Text] [Related]
39. Identification of microRNA signature and potential pathway targets in prostate cancer.
Moustafa AA; Ziada M; Elshaikh A; Datta A; Kim H; Moroz K; Srivastav S; Thomas R; Silberstein JL; Moparty K; Salem FE; El-Habit OH; Abdel-Mageed AB
Exp Biol Med (Maywood); 2017 Mar; 242(5):536-546. PubMed ID: 27903835
[TBL] [Abstract][Full Text] [Related]
40. Methylation-associated silencing of
Chen K; Liu MX; Mak CS; Yung MM; Leung TH; Xu D; Ngu SF; Chan KK; Yang H; Ngan HY; Chan DW
Theranostics; 2018; 8(2):423-436. PubMed ID: 29290818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
